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neurogenic bladder disease, were invited to participate for a 
response rate of 50 %. At baseline, 1,610 men were included. 
CVD status was compared to LUTS category, using logis-
tic regression, providing odds ratios with 95 % confidence 
intervals (OR 95 % CI). For the longitudinal analyses in men 
without CVD at baseline, hazard ratios (HR) and 95 % CI 
were estimated using Cox proportional hazard models with 
the occurrence of a CVD as outcome variable.
Results At baseline, 362 men (22 %) had a history of 
CVD. The ORs for CVD for men with moderate to severe 
LUTS were 2.04 (unadjusted, 95 % CI 1.58–2.63), 1.86 
(1.43–2.41, adjusted for age), and 1.81 (1.38–2.37, adjusted 
for age and other confounders). Of the 1,248 CVD-free 
men, 58 (4.6 %) had a CVD event. HRs for moderate to 
severe LUTS were 0.98 (95 % CI 0.52–1.86, unadjusted) 
and 1.08 (0.57–2.07, adjusted for age, obesity, hyperten-
sion, and erectile dysfunction).
Conclusions The cross-sectional analyses revealed a clear 
correlation between moderate to severe LUTS and CVD. In 
longitudinal analyses, however, no significant association 
was shown.
Keywords Lower urinary tract symptoms · 
Cardiovascular disease · Cohort study · LUTS
Introduction
Cardiovascular diseases (CVD) and lower urinary tract 
symptoms (LUTS) are health problems that are becoming 
more prevalent in the aging population [1, 2]. As CVD have 
a high incidence of morbidity and mortality, it is important 
to find patients at risk [3]. Previously, it has been suggested 
that LUTS are associated with CVD and may predict sub-
sequent cardiovascular events [4–9].
Abstract 
Purpose To describe the association between lower uri-
nary tract symptoms (LUTS) and cardiovascular diseases 
(CVD), with adjustment for age and other confounders. We 
were specifically interested in the possible predictive value 
of LUTS to the incidence of CVD in the future in the gen-
eral population.
Methods We performed post hoc analyses using data from 
the Krimpen study, a large community-based study in the 
Netherlands. All men aged 50–75 years, without prostate 
or bladder cancer, a history of radical prostatectomy, or 
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This may be explained by the fact that LUTS and CVD 
share risk factors such as obesity, diabetes, hypertension, 
smoking, and aging [4–9]. These well-known vascular risk 
factors might also impact LUTS through various pathways 
from vascular diseases [4–9]. However, the results of stud-
ies, describing the association between LUTS and CVD, 
are diverse and conflicting [4–13]. There are several small 
clinical studies of referred men at urologic clinics [4–6], 
analyzing multiple risk factors, sometimes without ade-
quate standardization or without adjustment for age [5]. As 
both CVD and LUTS are highly age related, the association 
between the two needs to be adjusted for age, or stratified 
analyses should be performed.
More recently, results of large community-based studies 
were published on the association between CVD and LUTS 
[10–12], or CVD and nocturia [9, 13]. Just four studies pre-
sented results from longitudinal analyses [10–13]. Lightner 
et al. reported on a community-based cohort study of 2,447 
men aged 40–79 years, with a median follow-up time of 
17.1 years. The presence of nocturia in men younger than 
60 years did not influence a chance of coronary heart dis-
ease development. In older men, nocturia coincided with an 
increased mortality risk [13]. Wherberger et al. [12] showed 
an increased CVD risk for men with severe LUTS in a 
community-based sample of 2,092 men aged 30–92 years. 
This group only included 17 men, representing 1 % of the 
total study population; men with moderate LUTS had no 
increased CVD risk [12]. From an epidemiological point of 
view, the clinical relevance of this result is doubtful. These 
limitations require additional study to address problems 
with those previous studies.
Especially, longitudinal data are needed to clarify this 
matter. We aim to describe the correlation between LUTS 
and CVD, with adjustment for age and other confounders. 
We were specifically interested in the possible predictive 
value of LUTS to the incidence of CVD in the future. For 
this, we used both cross-sectional data as well as longitudi-
nal data from a large population-based study.
Materials and methods
Patients and data collection
We performed post hoc analyses using the data of the 
Krimpen Study: A large community-based study on 
male urogenital tract problems and general health status 
described in detail earlier [14, 15]. In short, all men in a 
Dutch municipality aged 50–75 years in June 1995 were 
selected from the public registry. Men with a history of rad-
ical prostatectomy, prostate or bladder cancer, neurogenic 
bladder disease, or who were unable to complete ques-
tionnaires or visit the healthcare- center were excluded. 
Figure 1 shows a flowchart of participant inclusion. All 
men provided written informed consent. The Medical Eth-
ics Committee of the Erasmus Medical Center Rotterdam, 
the Netherlands, approved the study.
At baseline, the participants completed a 113-term, 
self-administered questionnaire including the International 
Prostate Symptom Score (IPSS) [16], the International 
Continence Society Male Sex Questionnaire (ICS sex) 
[17], and questions on treatment for chronic diseases. Par-
ticipants completed a 3-day frequency–volume chart and 
visited the local health center for physical examination, 
including blood pressure, height, body weight measure-
ments, and collection of data on current drug use [15].
The electronic medical records of the general practition-
ers (GPs) were used to collect data on death (exact date 
and cause) and cardiovascular events, including records 
and history until spring 2003. In the Netherlands, GPs 
have a central role in keeping medical histories of patients. 
Patients are obliged to be registered at a single general 
practice only. GPs store their patient data in a computer-
ized system and code their medical records using the Inter-
national Classification of Primary health Care (ICPC) [18]. 
Complete GP records were obtained for 1,622 participants 
(98 %), and data (myocardial infarction, stroke, transient 
ischemic attack, and sudden death) were extracted accord-
ing to a predefined protocol [19].
Definitions
From all identified records of a possible cardiovascular event, 
the medical files and hospital discharge letters were blinded 
and examined by two experts, i.e. a cardiologist (all files) 
and a GP or a researcher [19]. In case of disagreement, both 
experts would re-examine the information about the event.
The following Antithrombotic Trialists’ Collaboration 
definitions for cardiovascular events were applied [20]. 
Acute myocardial infarction (AMI): All events with posi-
tive relevant biomarkers, acute electrocardiography ST-
segment elevations followed by administration of fibrino-
lytics, or a positive myocardial scintigraphy with related 
documented clinical symptoms occurred within 6 months 
of scintigraphy. Stroke: Central neurological deficits docu-
mented by a neurologist or GP with duration >24 h and/or 
a positive cerebral CT-scan for stroke. Sudden death: Death 
that occurred ‘suddenly and unexpectedly’ with no other 
plausible explanation than vascular disease.
For each participant, we defined CVD status at baseline 
as being present (AMI or stroke before inclusion in the 
study) or absent. For each person without CVD at base-
line, we defined CVD at follow-up as positive in case of 
an AMI, stroke, or sudden death. For these participants, 
the duration of follow-up was defined as the time period 
between baseline measurement and the occurrence of a first 
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cardiovascular event. For all other participants, duration of 
follow-up was defined as the period between baseline and 
time of moving out of the area, or time of record obtaining.
We categorized LUTS severity, based on IPSS scores, as 
none/mild (0–7), moderate (8–19), and severe (≥20) [15]. 
We defined erectile dysfunction using the ICS sex question-
naire, as a report of “no erections” or “erections of reduced 
rigidity” [21]. Furthermore, the following definitions were 
applied: hypertension (diastolic blood pressure >94 mm Hg, 
systolic blood pressure >159 mm Hg, or use of antihyperten-
sive drugs), obesity (BMI: >30 kg/m2—calculated by divid-
ing weight by the square of height), and diabetes mellitus (a 
self-reported presence of diabetes or the use of antidiabetic 
drugs, i.e. oral medication or insulin). Finally, we dichoto-
mized smoking as yes or no, and categorized alcohol use as 
none, 1–2 units, or >2 units of alcohol per day.
Statistical analyses
Association between CVD and LUTS in cross‑sectional 
analyses
To allow comparisons to other cross-sectional studies, 
we measured the possible association between LUTS and 
Fig. 1  Selection process of men 
free of cardiovascular disease at 
baseline (n = 1,248) [19]
 World J Urol
1 3
CVD at baseline, using the chi-square test for linearity. 
Additionally, we performed logistic regression analyses 
with CVD status as the dependent variable and LUTS 
as the explanatory variable. To correct for the expected 
strong correlation between both LUTS and CVD with 
age, we first adjusted for age in multivariable logistic 
regression.
Next, we adjusted for the following possible confound-
ers known to be related to CVD: hypertension, diabetes 
mellitus, smoking status, erectile dysfunction, alcohol 
consumption, and obesity. A stepwise backward logistic 
regression analysis was performed, and the final model is 
presented. Resulting odds ratios (OR) for the different vari-
ables are presented, with 95 % confidence intervals (95 % 
CI). Additionally, the Nagelkerke R-square statistic was 
used to estimate the percentage of variance of the outcome 
measure explained by the model [22].
LUTS as a predictor of CVD
To test the predictive value of LUTS on subsequent CVD, 
we selected all men without CVD at baseline and catego-
rized them according to LUTS severity. We performed Cox 
regression analyses with the occurrence of a CVD as out-
come variable. For those subjects who were still alive when 
they were lost to follow-up or when the observation period 
ended, right censoring will occur.
First, bivariate analyses were performed using LUTS 
severity as the explanatory variable. As we expected an 
age-dependent association between LUTS and CVD, we 
first added age to the multivariable model.
Subsequently, the following possible confounders 
were added in separate Cox regression models: hyperten-
sion, diabetes mellitus, smoking status, alcohol consump-
tion, obesity, and erectile dysfunction. If this resulted in 
a change of the beta coefficient for LUTS severity with 
≥10 %, we added the variable to a final multivariable 
model. Resulting hazard ratios (HR) for the different var-
iables are presented with 95 % CI. Finally we added an 
interaction variable (age*LUTS) to the final model to rule 
out effect modification. If the significance level of this 
interaction variable is larger than 0.05, effect modification 
is ruled out.
Post hoc power calculations showed that the number of 
men included in our study would allow detecting a 3 % dif-
ference in CVD risk between men with and without LUTS. 
This would mean a relative risk of 50 % (6 % compared to 
9 %), which we believe would be clinically relevant.
We refrained from doing subgroup analyses, due to the 
small number of CVD events included in our study.
All statistical analyses were performed with SPSS ver-
sion 20.0.
Results
The baseline characteristics of the study population are pre-
sented in Table 1.
Cross-sectional analyses
We included 1,610 men in the cross-sectional analyses. 
Of these, 362 men (22 %) had a history of CVD before 
inclusion in the study. Men with none/mild LUTS, mod-
erate LUTS, and severe LUTS, respectively, had 19.2 % 
(95 % CI 17.1–21.5), 32.0 % (28.1–38.1), and 37.5 % 
(25.2–51.6) CVD history (chi-square test for linearity, 
p < 0.001). Due to small numbers in the moderate and 
severe LUTS categories, we combined these groups in the 
further analysis.
The OR for CVD for men with moderate to severe 
LUTS were 2.04 (unadjusted, 95 % CI 1.58–2.63), 1.86 
(adjusted for age 1.43–2.41), and 1.81 (multivariable 
adjustment, 1.38–2.37) (Table 2). The variables diabe-
tes, smoking, alcohol, hypertension, and obesity dropped 
out during the analysis and were excluded for the final 
model. The Nagelkerke R-square for this final model was 
0.06.
Table 1  Baseline characteristics of 1,610 included men
n Mean/events SD
Age (mean, SD) 1,609 61.4 6.6
Age groups (years)
 50–54 326 20.3 %
 55–59 407 25.3 %
 60–64 392 24.4 %
 65–69 309 19.2 %
 70 and older 175 10.9 %
LUTS severity 1,610 5,032 (median) IQR 1–4
 None/mild 1,218 75.7 %
 Moderate 344 21.4 %
 Severe 48 3.0 %
Prostate volume (mean, SD) 1,562 33.8 ml 14.5
Q-max (mean, SD) 1,408 11.4 ml/min 6.9
Cardiovascular disease (n, %) 1,610 445 26.3 %
Diabetes mellitus (n, %) 1,610 54 3.4 %
Hypertension (n, %) 1,570 168 10.7 %
Current smoking (n, %) 1,610 391 24.3 %
Use of alcohol (n, %) 1,610
 1–2 units/day 939 58.3 %
 2 units/day 300 18.6 %
Body mass index (BMI) (mean, 
SD)
1,567 26.0 2.9
Obesity (BMI > 30) (n, %) 149 9.5 %
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Longitudinal analysis
We included 1,248 CVD-free men in the longitudinal 
analyses. The mean follow-up time was 6.35 years (range 
0.10–8.34, total 7,945 person-years). During follow-up, 58 
participants (4.6 %) had a cardiovascular event (39 AMI, 
14 strokes, sudden death five men). Forty-six (4.7 %) cases 
occurred in men with no or mild LUTS and 12(4.5 %) in 
men with moderate to severe LUTS. The unadjusted HR 
for LUTS was 0.98 (95 % CI 0.52–1.86, p = 0.956). Alco-
hol consumption had no relevant confounding effect.
Multivariable Cox proportional regression analyses, 
with adjustment for age, obesity, hypertension, diabetes 
mellitus, current smoking, and erectile dysfunction, yielded 
a HR of 1.08 (95 % CI 0.57–2.07; p = 0.810) for moderate 
to severe LUTS. Effect modification by age was ruled out 
(p = 0.261, for the interaction variable) (Table 3).
Discussion
In this population-based study, we could not confirm a 
causal relation between LUTS and CVD; we found an 
obvious association in the cross-sectional part but not in the 
longitudinal part of our study.
There are diverse hypotheses on the relationship 
between LUTS and CVD, and its pathophysiology, illus-
trated in Fig. 2. The pathogenesis of LUTS is considered 
to be multifactorial, in which age-related changes of blad-
der structure/function seem to play a central role. Vascu-
lar diseases such as atherosclerosis and endothelial dys-
function in the pelvic vascular system might contribute to 
bladder dysfunction with age [4]. Increased sympathetic 
activity and/or a1-adrenoreceptor activity might be a com-
mon pathway for both hypertension and LUTS [23]. Risk 
factors for vascular diseases/atherosclerosis might also 
have an impact on LUTS via other mechanisms. Nico-
tine, for instance, increases sympathetic nervous system 
activity and may contribute to LUTS via an increase in 
the tone of the prostate [24]. Diabetes mellitus can lead to 
LUTS via neurogenic bladder dysfunction with detrusor 
underactivity being the most common urodynamic pattern 
[4].
Recently, Wehrberger et al. [12] were the first to show 
an increased risk of CVD in community-dwelling men with 
severe LUTS in both cross-sectional and longitudinal set-
ting. In that study, Austrian men visiting the department of 
preventive health of the city of Vienna and employees of 
large companies were invited for participation. We believe 
that this could possibly have resulted in a biased popula-
tion of generally healthy subjects. More recently, Bouw-
man et al. [10] did not confirm this association; however, 
this was a primary care population. In our study, participant 
characteristics were comparable to the general Dutch male 
population, albeit that the non-Caucasian men were under-
represented. As the risk factors for CVD differ between 
races, the association between CVD and LUTS may also 
differ [25].
Nocturia, a subcategory of LUTS, has also been studied 
as a possible predictor of CVD [13, 26, 27]. It has been sug-
gested that nocturia causes sleep disturbances, blood pres-
sure variability, increased sympathetic activity, and non-
dipping blood pressure variations, all risk factors for CVD 
[26, 27]. Recently, large population-based studies reported 
on the association between nocturia and (cardiovascular) 
mortality. In the NHANES study, a significant trend in 
increased risk of mortality with higher nocturnal voiding 
frequency episodes was described [26]. Analysis showed 
a multivariate association between nocturia and mortality 
(HR 1.49, 95 % CI 1.25–1.78) in men. More recently, Van 
Doorn et al. [27] did not confirm this association, showing 
a univariate association between nocturia and mortality that 
disappeared after adjustment for age. This suggests that the 
Table 2  The association between LUTS and CVD from cross-sec-
tional analyses, final multivariable logistic regression model
Results of multivariable logistic regression analyses. Variables 
entered on the first step: age groups, diabetes mellitus, current smok-
ing, use of alcohol, hypertension, obesity (BMI > 30), LUTS (IPSS > 
7), and erectile dysfunction
Odds ratio 95 % CI p value
Age groups (years)
 50–54 Reference <0.01
 55–59 0.92 0.61–1.83
 60–64 1.56 1.06–2.29
 65–69 1.83 1.22–2.73
 70–78 2.04 1.29–3.22
LUTS (IPSS > 7) 1.81 1.38–2.37 <0.01
Erectile dysfunction 1.63 1.14–2.34 <0.01
Table 3  The association between LUTS and CVD from longitudinal analyses, final model
Asterisk refers to the confounds from the multivariate analysis
Variables entered on the first step: age groups, diabetes mellitus, current smoking, use of alcohol, hypertension, obesity (BMI > 30), LUTS 
(IPSS > 7), and erectile dysfunction
Outcome Unadjusted HR (95 % CI) Multivariate adjusted HR (95 % CI)*
CVD (incl. AMI, stroke, sudden death) 0.98 (0.52–1.86) 1.08 (0.57–2.07)
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association between nocturia and mortality may be an age-
related association and not a causal relation in itself.
Although both CVD and LUTS are age dependent, no 
effect modification was found in our study. We chose not 
to test effect modification in the cross-sectional part, as we 
believed that this is less important, because in such analy-
ses, causal inference cannot be made.
Also CVD events or associated treatment might influ-
ence the occurrence and severity of LUTS. This “reverse” 
causality may have influenced the baseline analyses/asso-
ciations. However, the time between CVD events before 
baseline was unknown, as was the LUTS status at time of 
these events. So, a causal association could not be proven.
We consider the large population-based sample of repre-
sentative participants a strength of our study [15]. Earlier, 
we showed a slight response bias [14, 15]. This has lim-
ited or no impact on the outcomes in the current analyses, 
because data on morbidity/mortality were collected from 
the GP medical records, irrespective of participation in the 
longitudinal part of the study. The prevalence of risk factors 
for CVD in the studied population was comparable to the 
general Dutch population [28, 29]. A notable exception to 
this is the prevalence of hypertension, which is 45 % in the 
general population and 9 % in our study [28, 29]. This was 
caused by a difference in applied definitions.
All identified records of patients with a CVD event 
were independently checked by an expert panel [19]. This 
resulted in a thorough categorization of CVD events based 
on the ATC definitions [20]. However, we were not able to 
include other cardiovascular problems such as angina pecto-
ris, atrium fibrillation, or heart failure. This may have biased 
the results of our study. Also, the database did not provide 
us with the total cholesterol and the high-density-lipopro-
tein values of all the participants at baseline. This may be 
regarded as a possible limitation of this study, as these val-
ues are important predictors for CVD. There is, however, 
conflicting evidence regarding the relation between LUTS 
and cholesterol or statin use [26, 30]. It appears that both 
high cholesterol levels and statin use (resulting in low cho-
lesterol levels) may contribute to the occurrence of LUTS. 
In our study, 3 % of all men had severe LUTS. We consid-
ered this group to be too small for statistical analyses and 
chose to combine the men with moderate and severe LUTS 
(together 24.3 %).
Fig. 2  Directed acyclic graph 
revealing pathofysiological 
patterns of LUTS and CVD,and 
their shared risk factors/poten-
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The association between LUTS and CVD may well 
be influenced by confounding factors. Therefore, based 
on previous literature, we have selected possibly relevant 
characteristics that were available in our database. Next, 
we tested if these variables indeed influenced the associa-
tion under study. From this, it appeared that only alcohol 
appeared to have no confounding effect.
We found a difference in CVD risk between men with 
and without LUTS of 1.2 % in the longitudinal part of our 
study. We therefore believe that the absence of a clinically 
relevant difference reflects a true negative result.
Conclusions
We conclude that LUTS and CVD commonly coincide. 
However, the presence of LUTS is not associated with sub-
sequent CVD in men with a CVD-free history in the Dutch 
general population.
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